Companies: 10,795·Total market cap: $144.5T
Bio-Techne Corporation

Bio-Techne Corporation

TECHNASDAQHealthcare● Active
$52.70
+$0.71(+1.36%)
Market Cap$8.3B
P/E Ratio—
52W High$72.16
52W Low$43.2
Overview

Bio-Techne Corporation (TECH) Cash on Hand — Cash & Short-Term Investments

Cash & cash equivalents plus short-term investments from the balance sheet, YoY change, and net cash vs debt context.

TECH · cash on hand · updated Jun 30, 2025

Core cash position

Cash & Short-Term Investments (CCE + ST Investments)
$162.2M▲ +6.1% vs prior year
FY · as of Jun 30, 2025 · Reported in USD
Cash & Cash Equiv. (CCE)
$162.2M
cashAndCashEquivalents
Short-Term Investments
$0
shortTermInvestments
YoY Change vs Prior Year
+6.1%
vs prior fiscal year
Latest Quarter
$209.8M
Q1 2026
Data Scope & Methodology

Cash on Hand = Cash & Cash Equivalents (CCE) + Short-Term Investments, as reported on the balance sheet (10-K/10-Q). Also referred to as cash reserves or cash position. Not free cash flow.

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · Reported in USD

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · USDUpdated: June 30, 2025

Net cash vs debt

Cash & ST Investments$162.2MCash on Hand
Total Debt$444.1MTotal Debt
Net Cash / Net Debt−$281.9MNet Debt Position
Cash vs Debt Ratio
Cash 27%Debt 73%

Bio-Techne Corporation carries a net debt position of $281.9M. Total debt ($444.1M) exceeds cash on hand ($162.2M). Bio-Techne Corporation cash vs debt ratio: 27% cash / 73% debt.

Net Cash = Cash & ST Investments − Total Debt$162.2M − $444.1M = −$281.9M

Cash on hand history

YoY Increase
YoY Decrease
Latest Year
TECH annual cash on hand history · Cash & Short-Term Investments · Source: FMP /balance-sheet-statement

Annual cash on hand by year

DateCash & ST InvestmentsYoY Change
Jun 30, 2025Latest$162.2M+6.1%
Jun 30, 2024$152.9M-25.2%
Jun 30, 2023$204.3M-17.3%
Jun 30, 2022$247.0M+6.7%
Jun 30, 2021$231.6M-14.5%
TECH cash on hand annual historical data · Cash & Short-Term Investments per balance sheet (10-K/10-Q) · Reported in USD · Source: FMP /balance-sheet-statement

Healthcare Sector Cash Reserves Comparison

#CompanyCash & ST Inv.Cash/MCap
#1
UnitedHealth Group Incorporated
UnitedHealth Group Incorporated
UNH
$28.12B7.7%#2
Johnson & Johnson
Johnson & Johnson
JNJ
$20.10B3.6%#3
Eli Lilly and Company
Eli Lilly and Company
LLY
$7.27B0.7%#4
AbbVie Inc.
AbbVie Inc.
ABBV
$5.26B1.3%
#5
Bio-Techne Corporation
Bio-Techne CorporationYOU
TECH
$162.2M2.0%
Healthcare sector cash reserves · Source: FMP /balance-sheet-statement + /profile · Sorted by Cash desccompanies with most cash on hand →

About cash on hand & methodology

Bio-Techne Corporation (TECH) cash on hand as of June 30, 2025 is $162.2M, comprising $162.2M in cash and cash equivalents (CCE) plus $0 in short-term investments — reported as Bio-Techne Corporation cash and short-term investments on the balance sheet (10-K filing). Also referred to as Bio-Techne Corporation cash reserves or cash position.

Bio-Techne Corporation annual cash on hand history shows increased +6.1% in 2025: increased +6.1% in 2025. Bio-Techne Corporation cash reserves in 2025 reflect the company's capital allocation strategy.

Bio-Techne Corporation carries total debt of $444.1M against cash of $162.2M, resulting in a net debt position of -$281.9M. For the full balance sheet, see the Financials → Balance Sheet tab.

Figures tie to SEC 10-K/10-Q balance sheet disclosures and FMP /balance-sheet-statement where noted.
Financial statementsFree cash flowNet incomeRevenueMarket capP/E ratioEarningsPrice history

Frequently asked questions

TECH cash on hand · 5 questions

As of June 30, 2025, Bio-Techne Corporation (TECH) has $162,186,000 in cash on hand — defined as cash and short-term investments on the balance sheet. This includes $162,186,000 in cash and cash equivalents (CCE) plus $0 in short-term investments. Latest quarter (March 31, 2026): $209,819,000. Data sourced from the annual 10-K filing via FMP.

TECH cash on handTECH cash reservesTECH cash 2025how much cash does TECH have

▸ Source: FMP /balance-sheet-statement · US GAAP · Bio-Techne Corporation · Bio-Techne Corporation SEC 10-K & 10-Q filings · US GAAP · Last updated: June 30, 2025